Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer ...

According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an ...

Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. | Astellas is aiding Vir ...

Vir Biotechnology (VIR) has drawn fresh investor attention after announcing a global collaboration with Astellas around VIR-5500, a dual-masked T-cell engager for metastatic castration-resistant ...

Vir stock catapulted Tuesday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma.

Astellas and Vir Biotechnology collaborate to advance PSMA-targeting PRO-XTEN dual-masked T-cell engager VIR-5500 to treat prostate cancer: Tokyo Wednesday, February 25, 2026, 09: ...

Vir Biotechnology Inc. VIR reported better-than-expected fourth-quarter earnings, anounced a significant strategic ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...

Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...

Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.

Vir Biotechnology and Astellas entered a license agreement to co-develop and commercialize Vir's prostate cancer treatment. The agreement is for VIR-5500, a dual-masked T-cell engager targeting ...

Vir has a promising pipeline, and expects to report data this year on several phase 2 clinical trials. Vir's revenue rose by 133.4% last year. The Food and Drug Administration recently made a decision ...